[go: up one dir, main page]

CO5680425A2 - Formulaciones liofilizadas de cci-779 - Google Patents

Formulaciones liofilizadas de cci-779

Info

Publication number
CO5680425A2
CO5680425A2 CO06017792A CO06017792A CO5680425A2 CO 5680425 A2 CO5680425 A2 CO 5680425A2 CO 06017792 A CO06017792 A CO 06017792A CO 06017792 A CO06017792 A CO 06017792A CO 5680425 A2 CO5680425 A2 CO 5680425A2
Authority
CO
Colombia
Prior art keywords
solution according
solvent
cci
solution
butyl alcohol
Prior art date
Application number
CO06017792A
Other languages
English (en)
Inventor
Joseph T Rubino
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5680425(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5680425A2 publication Critical patent/CO5680425A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1.- Una solución útil para preparar CCI-779 secada por congelamiento, caracterizada porque comprende 0.1 mg/ml, a 250 mg/ml de CCI-779 y por lo menos 30% v/v de solvente seleccionado del grupo que consiste de dimetilsulfóxido, acetonitrilo, etanol, isopropanol, alcohol t-butílico y mezclas de los mismos que opcionalmente además contienen agua.2.- La solución de conformidad con la reivindicación 1, caracterizada porque la solución comprende 40% v/v de agua y tiene un pH en un intervalo de 4 a 6.3.- La solución de conformidad con la reivindicación 1, caracterizada porque la solución comprende 40% a 70% v/v de solvente.4.- La solución de conformidad con la reivindicación 1, caracterizada porque el solvente comprende alcohol t-butílico.5.- La solución de conformidad con la reivindicación 1, caracterizada porque el solvente es etanol.6.- La solución de conformidad con la reivindicación 4, caracterizada porque el solvente comprende alcohol t-butílico que está en el intervalo de 40 a 60% v/v de alcohol t-butílico en agua.7.- La solución de conformidad con la reivindicación 1, caracterizada porque contiene agua en donde el pH es aproximadamente 5.5.
CO06017792A 2003-07-25 2006-02-22 Formulaciones liofilizadas de cci-779 CO5680425A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49029303P 2003-07-25 2003-07-25

Publications (1)

Publication Number Publication Date
CO5680425A2 true CO5680425A2 (es) 2006-09-29

Family

ID=34115376

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06017792A CO5680425A2 (es) 2003-07-25 2006-02-22 Formulaciones liofilizadas de cci-779

Country Status (20)

Country Link
US (1) US20050020615A1 (es)
EP (1) EP1648454A1 (es)
JP (1) JP2007500191A (es)
KR (1) KR20060052880A (es)
CN (1) CN1829514A (es)
AR (1) AR045094A1 (es)
AU (1) AU2004261163A1 (es)
BR (1) BRPI0412916A (es)
CA (1) CA2532251A1 (es)
CO (1) CO5680425A2 (es)
CR (1) CR8153A (es)
EC (1) ECSP066394A (es)
IL (1) IL172573A0 (es)
MX (1) MXPA05013865A (es)
NO (1) NO20056178L (es)
RU (1) RU2345772C2 (es)
SG (1) SG144165A1 (es)
TW (1) TW200505501A (es)
WO (1) WO2005011688A1 (es)
ZA (1) ZA200600684B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011000A1 (en) 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
ES2298861T3 (es) * 2004-01-08 2008-05-16 Wyeth Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.
JP5117190B2 (ja) * 2004-08-27 2013-01-09 コーディス・コーポレイション 溶媒を含有しない非晶質ラパマイシン
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP5670335B2 (ja) * 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
BRPI1004922A2 (pt) * 2009-01-15 2019-09-24 Cephalon Inc composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama
JP2013527223A (ja) * 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
WO2013117969A1 (en) 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CN102940630A (zh) * 2012-11-16 2013-02-27 浙江海正药业股份有限公司 含有西罗莫司酯化物的药物组合物及其制备方法
WO2014118696A2 (en) * 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104510708B (zh) * 2013-09-29 2018-04-24 正大天晴药业集团股份有限公司 一种米铂冻干制剂及其制备方法
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法
CN107773539A (zh) * 2016-08-27 2018-03-09 鲁南制药集团股份有限公司 一种注射用坦西莫司及其制备方法
CN111165656A (zh) * 2020-01-09 2020-05-19 南京大学（溧水）生态环境研究院 一种黑水虻冻干粉高效制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204775B (it) * 1986-01-31 1989-03-10 Rosella Silvestrini Kit per la determinazione dell'attivita' proliferativa nei tumori umani
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
KR100400620B1 (ko) * 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
GB9514594D0 (en) * 1995-07-17 1995-09-13 Johnson & Johnson Clin Diag Chemiluminescent analytical method
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
DE19936281C2 (de) * 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CN100448487C (zh) * 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
WO2004011000A1 (en) * 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
ES2315530T3 (es) * 2002-09-17 2009-04-01 Wyeth Formulacion granulada de un ester de rapamicina cci-779.
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція

Also Published As

Publication number Publication date
EP1648454A1 (en) 2006-04-26
RU2006105645A (ru) 2006-06-27
CA2532251A1 (en) 2005-02-10
KR20060052880A (ko) 2006-05-19
CR8153A (es) 2006-05-26
ZA200600684B (en) 2008-07-30
TW200505501A (en) 2005-02-16
SG144165A1 (en) 2008-07-29
AR045094A1 (es) 2005-10-12
BRPI0412916A (pt) 2006-09-26
NO20056178L (no) 2006-02-17
US20050020615A1 (en) 2005-01-27
CN1829514A (zh) 2006-09-06
JP2007500191A (ja) 2007-01-11
MXPA05013865A (es) 2006-02-28
AU2004261163A1 (en) 2005-02-10
RU2345772C2 (ru) 2009-02-10
ECSP066394A (es) 2006-08-30
WO2005011688A1 (en) 2005-02-10
IL172573A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
CO5680425A2 (es) Formulaciones liofilizadas de cci-779
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
EA200300050A1 (ru) Гликопептидфосфонатные производные
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
BR0211905A (pt) Dialdeìdos de rapamicina
AR034456A1 (es) Champues con alcohol de behenilo
UY25671A1 (es) Procedimiento para preparar imidazotrazinonas sustituidas por 2-fenilo
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR032497A1 (es) Limpiador antimicrobiano acido para superficies duras
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
NO940523L (no) Nye pyrazin-derivater
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
SE0000774D0 (sv) New formulation
DK1212039T3 (da) Sammensætning til inhalation omfattende delta-9-tetrahydrocannabinol i et semivandigt oplösningsmiddel
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
CO5560531A2 (es) Producto antitranspirante con dibencilideno sorbitol y elastomero en dimeticona
ATE340591T1 (de) Pharmazeutische lösungen von triphenylethylen- antiöstrogenen
CO4970704A1 (es) Solucion acuosa estable de em 12, y procedimiento de preparacion de dicha solucion
AR014320A1 (es) Compuestos de (2r,3s,4s,5r,6r,10r,11r)-2,4,6,8,10-pentametil-11-acetil-12, 13-dioxabiciclo[8.2.1]tridec-8-en-1-ona, medicamentos que contienen estoscompuestos y procedimiento para la preparacion de dichos compuestos
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
AR023979A1 (es) Procesos para preparar compuestos intermedios de plaguicidas
RU2000118409A (ru) Антимутагенное средство
ES2550136T3 (es) Preparaciones anti-víricas potenciales de 5'-fosfanato azidotimidina modificado
UY28267A1 (es) Composicion agroquimica en suspension acuosa